Skip to main content

Table 5 Univariate and multivariate analysis with post-recurrence survival after recurrence

From: Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer

Parameters

Univarite analysis

Multivarite analysis

Hazard ratio

95% CI

p value

Hazard ratio

95% CI

p value

Age at operation (years old)

 ≤ 60 versus > 60

0.871

0.040–9.101

0.910

   

Tumor size (mm)

 ≤ 20.0 versus > 20.0

1.798

0.172–38.728

0.623

   

Tumor size (mm)

 ≤ 30.0 versus > 30.0

–

–

0.265

   

Pathological lymph node metastasis

pN0, pN1mi versus pN1a

21.520

1.878–488.577

0.016

17.339

1.112–530.855

0.042

Progesterone receptor

Negative versus positive

–

–

0.545

   

Ki67

 ≤ 20% versus > 20%

1.806

0.084–18.864

0.642

   

Surgical treatment

BCT and radiation therapy versus mastectomy

0.422

0.020–4.410

0.467

   

Lymphatic invasion

ly0 versus ly1

1.906

0.182–41.094

0.589

   

Venous invasion

v0 versus v1

3.760

0.174–39.725

0.327

   

Nuclear grade

1, 2 versus 3

–

–

0.294

   

Adjuvant endocrine therapy

TAM (+ LH-RH agonist) versus ANA

0.422

0.020–4.410

0.467

   

Disease free survival (days)

 ≤ 1462 versus > 1462

1.229

0.056–13.152

0.870

   

Primary recurrence site

Locoregional recurrence versus Distant metastasis

9.331

0.877–202.892

0.063

6.057

0.414–178.741

0.187

TILs density

 ≤ 10 versus > 10

3.405

0.158–35.582

0.360

   

TILs

Absent versus Not absent

0.211

0.018–4.800

0.269

   
  1. CI confidence intervals, BCT breast conserving treatment, TAM tamoxifen, LH-RH luteinizing hormone-releasing hormone, ANA anastrozole, TILs tumor- infiltrating lymphocytes